Press releases – Oncopeptides

Bulletin from the Extraordinary General Meeting in Oncopeptides AB (publ)

December 17, 2019 - Regulatory press release

Stockholm, Sweden – 17 December 2019 – An Extraordinary General Meeting in Oncopeptides AB (publ) (ONCO) was held today, at Tändstickspalatset in Stockholm. At the Extraordinary General Meeting, the foll...

Oncopeptides presents promising data from the Phase 2 ANCHOR combination study in patients with RRMM at ASH Annual Meeting 2019

December 8, 2019 - Regulatory press release

STOCKHOLM — December 8, 2019 — Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present updated data from the ongoing Phase 2 ANCHOR (OP-104) triple combination study at the ASH Annual Meeting 2019. In ...

Oncopeptides presents updated efficacy and safety data from pivotal Phase 2 HORIZON study in patients with RRMM at ASH Annual Meeting 2019

December 7, 2019 - Regulatory press release

STOCKHOLM — December 7, 2019 — Oncopeptides AB (Nasdaq Stockholm: ONCO) will today present follow-up data from the pivotal Phase 2 HORIZON (OP-106) study at the ASH Annual Meeting 2019. Melflufen showed an ...

Oncopeptides will host a webcast on Tuesday, December 10[th] at 13:00 (CET) to provide an update regarding data presented at the ASH annual meeting

December 6, 2019 - Other press release

Stockholm – December 6, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO), announces today that the company will host a webcast on Tuesday, December 10[th], 2019, at 13:00 (CET) to provide an update reg...

Oncopeptides appoints Joseph Horvat as President North America

December 2, 2019 - Other press release

Stockholm – December 2, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Joseph Horvat has been appointed as President North America and CEO of Oncopetides Inc. Joseph will serve o...

Interim Report Q3 2019

November 19, 2019 - Regulatory press release

Summary Financial overview July 1 – September 30, 2019 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 189.8 M (loss: 94.0) Loss per share, before and after dilution, was SEK 3.53 (...

Extraordinary General Meeting in Oncopeptides AB (publ)

November 14, 2019 - Regulatory press release

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend an Extr...

Oncopeptides to Highlight Data from Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019

November 6, 2019 - Other press release

STOCKHOLM — November 6, 2019 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that data from the clinical program evaluating its lead candidate melflufen in multiple myeloma and Light Chain (AL...

Number of shares and votes in Oncopeptides

October 31, 2019 - Regulatory press release

Stockholm — 31 October 2019 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the...

Nomination Committee appointed in respect of AGM 2020 in Oncopeptides

October 10, 2019 - Regulatory press release

Stockholm - October 10, 2019 - According to the principles for the appointment of the Nomination Committee in Oncopeptides AB adopted at the annual general meeting held on May 21st, 2019, the Nomination...

Number of shares and votes in Oncopeptides

September 30, 2019 - Regulatory press release

Stockholm — 30 September 2019 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the...

Patient recruitment in the Pivotal Phase 2-Study HORIZON completed

September 26, 2019 - Other press release

Stockholm - September 26, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the last patient has been included in the OP-106 HORIZON pivotal phase 2 clinical study evaluating melflufen...

Exercise of options and sale of shares under the Employee Stock Option Program 2012/2019

September 24, 2019 - Regulatory press release

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that all stock options 1) held by management team members under the Employee Stock Option Program 2012/2019 with associated warrants...

New Interim Data in RRMM Patients with Extramedullary Disease from the Pivotal Phase 2 Horizon-study presented at International Myeloma Workshop

September 15, 2019 - Regulatory press release

Stockholm – September 15, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today updated interim efficacy and safety data from the ongoing pivotal Phase 2 study, HORIZON, at the 17th International M...

Oncopeptides Announces Two Poster Presentations at the International Myeloma Workshop

September 14, 2019 - Other press release

Stockholm – September 14, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that our two poster presentations have been made public at the 17th International Myeloma Workshop (IMW) m...

Data from Oncopeptides Melflufen Clinical Development Program Presented at SOHO 2019 Annual Meeting

September 11, 2019 - Other press release

Stockholm – September 11, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that clinical trial data were presented at the Society of Hematologic Oncology (SOHO) 2019 Annual Meeting in ...

New updated data will be presented from Oncopeptides’ Pivotal Phase 2 HORIZON study in patients with extra medullary disease (EMD) on September 15th

August 30, 2019 - Other press release

Stockholm - 30 August 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that new updated melflufen data from the Phase 2 pivotal OP-106 HORIZON study will be presented at at the 17th...

Interim Report Q2 2019

August 28, 2019 - Regulatory press release

Summary

Oncopeptides appoints Klaas Bakker as new Chief Medical Officer

August 20, 2019 - Regulatory press release

Stockholm - August 20, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announces that Klaas Bakker has been appointed as the new Chief Medical Officer (CMO) for Oncopeptides, starting...

Oncopeptides Announces Acceptance of Data for Presentation at International Myeloma Workshop, September 12-15

August 16, 2019 - Other press release

Stockholm – August 16, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today the acceptance of an oral late breaking presentation providing updated melflufen data from the Phase 2 pivotal O...

Number of shares and votes in Oncopeptides

July 31, 2019 - Regulatory press release

Stockholm — 31 July 2019 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of the issue of 5,015,000 shares, whi...

Oncopeptides has completed a directed share issue of approximately SEK 727 million (USD 78 M)

June 28, 2019 - Regulatory press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, ISRAEL, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION...

Oncopeptides intends to make a directed share issue

June 27, 2019 - Regulatory press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, ISRAEL, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION...

New Data Presented from Oncopeptides’ Pivotal Phase 2 HORIZON Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma at 24th EHA Congress

June 16, 2019 - Regulatory press release

Stockholm - 16 June 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today updated interim efficacy and safety data from the ongoing, pivotal Phase 2 HORIZON trial. The oral presentation was included...

New Data Presented at 24th EHA Congress from Oncopeptides’ Phase 1/2 ANCHOR Trial Evaluating Melflufen in Relapsed/Refractory Multiple Myeloma (RRMM)

June 14, 2019 - Regulatory press release

Stockholm - 14 June 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO), announced today new data presented at the 24th Congress of the European Hematology Association (EHA) in Amsterdam, including updated...

Oncopeptides will host a Webcast on Monday, 17 June at 09:00 (CET) to review and update presentations from European Hematology (EHA) meeting

June 13, 2019 - Other press release

Stockholm – 13 June 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO), announces today that the company will make a review and update on the presented data from the European Hematology Meeting (EHA) on ...

New Data from Oncopeptides Phase 1/2 O-12-M1 Trial Evaluating Melflufen in RRMM Presented at 2019 ASCO Annual Meeting

June 3, 2019 - Other press release

Stockholm - 3 June 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO), a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological cancers, announced today...

Oncopeptides to present at the Jefferies Healthcare Conference in New York on June 7th at 11.30am EST

May 28, 2019 - Other press release

Stockholm – May 28, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that they will attend the Jefferies annual Healthcare Conference in New York between June 4-7th and make a plenum pre...

BULLETIN FROM THE ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)

May 21, 2019 - Regulatory press release

Stockholm, Sweden – 21 May 2019 – Oncopeptides AB (publ)’s (ONCO) Annual General Meeting 2019 was held today, at Tändstickspalatset in Stockholm. At the Annual General Meeting, the following principal resolu...

Interim Report Q1 2019

May 21, 2019 - Regulatory press release

Summary of Q1 “The initiation of the filing process for melflufen in the US is a major milestone for Oncopeptides.”

Oncopeptides to Apply for Accelerated Approval in the US

May 20, 2019 - Regulatory press release

Stockholm – May 20, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that, after discussions with the FDA, the company has initiated the preparation for submitting a New Drug Application (...

Oncopeptides Announces Acceptance of Four Abstracts Highlighting Melflufen Clinical Programs for Presentation at 24th EHA Congress in June 2019

May 16, 2019 - Regulatory press release

Stockholm – May 16, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that a total of four abstracts have been accepted for presentation at the 24th Congress of European Hematology Association (...

Oncopeptides Announces Melflufen Data Accepted for Presentation at 2019 ASCO Annual Meeting

May 15, 2019 - Regulatory press release

Stockholm – May 15, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that data from its Phase 1/2 O-12-M1 study evaluating melflufen, a lipophilic peptide-conjugated alkylator belonging to ...

Oncopeptides Annual Report for 2018

April 26, 2019 - Regulatory press release

Stockholm – 26 April 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the Annual Report for 2018 now is available at the company’s website, www.oncopeptides.com and can be found under...

Oncopeptides provides new guidance on the patient recruitment in the OCEAN study and a clinical program update in a webcast at 10:00 (CET)

April 24, 2019 - Regulatory press release

Stockholm – 24 April 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the company will provide an update on patient recruitment in the ongoing phase 3 study OCEAN, as well as a general u...

ANNUAL GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)

April 16, 2019 - Regulatory press release

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annual ...

Updated financial calendar

April 11, 2019 - Other press release

Stockholm - April 11, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that it has updated its financial calendar, the interim report for Q2 2019 have been moved to 28 August. The dates...

Additional patent protection for melflufen granted in the US until 2033

April 10, 2019 - Other press release

Stockholm - 10 April 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that the US patent and trademark office has issued a notice that they intend to grant additional patents to Oncopeptides...

Data from Oncopeptides Clinical Trials HORIZON and ANCHOR Evaluating Melflufen in RRMM Selected for Presentation at the AACR Annual Meeting

February 27, 2019 - Other press release

Stockholm — 27 February 2019 — Oncopeptides AB (Nasdaq Stockholm: ONCO) today announced that data from its Phase II HORIZON study and Phase I/II ANCHOR study evaluating the company’s...

Oncopeptides to present at the Cowen and Company Annual Healthcare Conference on Monday 11th March at 4:10 pm Eastern Standard Time

February 25, 2019 - Other press release

Stockholm – February 25, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Jakob Lindberg, CEO at Oncopeptides, will present the company at Cowen and Company 39th Annual Healthcare Con...

Year-end Report 2018

February 22, 2019 - Regulatory press release

Summary of Q4 Financial overview October 1 – December 31, 2018 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 111.4 M (loss: 66.2) Loss per share, before and after dilution, was 2.53 (...

Oncopeptides will host a webcast in conjunction with its Year-end Report 2018 on 22 February at 14:00 (CET)

February 18, 2019 - Other press release

Stockholm —18 February 2019 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the Company will release its Year-end Report on 22 February at 8:00 am CET. The report will be available on ...

Number of shares and votes in Oncopeptides

January 31, 2019 - Regulatory press release

Stockholm —31 January, 2019 — Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of the issue of 4,750,000 shares, whi...

Oncopeptides has completed a directed share issue of approximately SEK 546 million

January 24, 2019 - Regulatory press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE...

Oncopeptides intends to make a directed share issue

January 23, 2019 - Regulatory press release

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION...

Global